Ceftobiprole: A novel, broad-spectrum cephalosporin with activity against methicillin-resistant Staphylococcus aureus

June 2010
American Journal of Health-System Pharmacy;6/15/2010, Vol. 67 Issue 12, p983
Academic Journal
Purpose. The pharmacology, antimicrobial activity, pharmacokinetics, pharmacodynamics, clinical efficacy, safety, and place in therapy of ceftobiprole are reviewed. Summary. Ceftobiprole, a novel, broadspectrum, parenteral cephalosporin, inhibits the cell-wall synthesis of penicillinbinding proteins (PBPs) PBP2a and PBP2x, responsible for the resistance in staphylococci and pneumococci, respectively. Ceftobiprole has good activity against gram-positive aerobes and anaerobes, and its activity against gram-negative aerobes and anaerobes is species dependent. Ceftobiprole is relatively inactive against Acinetobacter species. Its ability to bind relevant PBPs of resistant gram-positive and gram-negative bacteria indicates its potential use in the treatment of hospital-acquired pneumonia and complicated skin and skin-structure infections (cSSSIs). Ceftobiprole is primarily excreted unchanged by the kidneys and exhibits linear pharmacokinetics. The half-life of the drug is approximately 3-4 hours. It exhibits minimal plasma protein binding (16%). Ceftobiprole does not inhibit the cytochrome P-450 isoenzyme system, so the possibility of drug-drug interactions is low. The drug has not been approved for use in the United States but has been approved in Canada and elsewhere. Ceftobiprole is currently undergoing Phase III clinical trials and has demonstrated activity against methicillin-resistant Staphylococcus aureus, penicillin-resistant Streptococcus pneumoniae, and Pseudomonas aeruginosa. Completed Phase III trials used i.v. dosages of 500 mg every 8-12 hours. The most commonly observed adverse effects of ceftobiprole included headache and gastrointestinal upset. Conclusion. Ceftobiprole is a novel, broadspectrum, parenteral cephalosporin undergoing Phase III clinical trials. Its broad spectrum of activity makes it a candidate for monotherapy of cSSSIs and pneumonias that have required combination therapy in the past.


Related Articles

  • Clinical Implications of Pharmacokinetics and Pharmacodynamics of Fluoroquinolones. Wispelwey, Brian // Clinical Infectious Diseases;7/15/2005 Supplement, Vol. 41, pS127 

    This review summarizes key data illustrating the clinical importance of pharmacodynamics, particularly among the fluoroquinolone family of antibacterials. Antibacterials are often divided into 2 groups�either time-dependent or concentration-dependent agents�on the basis of their...

  • Clinical Pharmacology of the Fluoroquinolones: Studies in Human Dynamic/Kinetic Models. Schentag, Jerome J. // Clinical Infectious Diseases;8/1/2000 Supplement 2, Vol. 31, pS40 

    Explores the clinical pharmacology of the fluoroquinolones by using data from studies of patients with nocosomial gram-negative pneumonia. Bacterial resistance; Bacterial eradication; Pharmacodynamics of newer quinolones; Multi-dose of pharmacokinetics of 4 fluoroquinolones.

  • Parámetros farmacodinámicos y farmacocinéticos de las fluoroquinolonas respiratorias. Guía para la selección de la fluoroquinolona más apropiada. Parra-Ruiz, Jorge; Hernández-Quero, José // Revista Española de Quimioterapia;dic2012, Vol. 25 Issue 4, p245 

    Since its approval, fluoroquinolones have become one of the most prescribed antibacterial agents. Because of its widespread use, serious concerns about the emergence of resistance in Streptococcus pneumoniae, Pseudomonas spp, and entrobacteriaceae, has arisen, especially because of...

  • Pharmacokinetics and Pharmacodynamics of Fluoroquinolones. Turnidge, J. // Drugs;Dec1999 Supplement 2, Vol. 58 Issue 6, p29 

    The fluoroquinolones have moderate to excellent bioavailability, moderate to long elimination half-lives (50 to 98%) and volumes of distribution >1.5 L/kg. There is considerable variation in elimination pattern between fluoroquinolone agents, ranging from predominant renal excretion to extensive...

  • Aminoglycoside Adaptive Resistance: Importance for Effective Dosage Regimens. Barclay, M.L.; Begg, E.J. // Drugs;Apr2001, Vol. 61 Issue 6, p713 

    There are various pharmacodynamic features of the aminoglycosides that are thought to contribute to the benefits of once-daily administration, of which the ability to induce adaptive resistance is the least understood and discussed. However, this may be the most important characteristic...

  • Quinolones in Community-Acquired Pneumonia; Are They Born Equal? Wadi, Jamal Ahmad // International Arabic Journal of Antimicrobial Agents;2012, Vol. 2 Issue 3, p1 

    There has been debate on the best treatment regimen for CAP, whether to start treatment with β-lactams, β-lactam β-lactamase inhibitor, macrolides, a combination of the earlier or quinolones, among other less commonly used agents. In this review, an attempt to examine some data on the...

  • Population pharmacokinetics and pharmacodynamic evaluation of intravenous and enteral moxifloxacin in surgical intensive care unit patients. Kees, Martin Georg; Schaeftlein, André; Haeberle, Helene Anna; Kees, Frieder; Kloft, Charlotte; Heininger, Alexandra // Journal of Antimicrobial Chemotherapy (JAC);Jun2013, Vol. 68 Issue 6, p1331 

    Objectives To describe the plasma concentration–time profile of moxifloxacin after intravenous and enteral administration in intensive care unit (ICU) patients and to provide a pharmacodynamic (PD) evaluation with regard to pneumonia. Patients and methods Twenty-five adult patients from a...

  • Comparative Pharmacokinetics and Pharmacodynamics of the Rifamycin Antibacterials. Burman, W.J.; Gallicano, K.; Peloquin, C. // Clinical Pharmacokinetics;2001, Vol. 40 Issue 5, p327 

    The rifamycin antibacterials, rifampicin (rifampin), rifabutin and rifapentine, are uniquely potent in the treatment of patients with tuberculosis and chronic staphylococcal infections. Absorption is variably affected by food; the maximal concentration of rifampicin is decreased by food, whereas...

  • Phage Therapy Pharmacology. Abedon, Stephen T.; Thomas-Abedon, Cameron // Current Pharmaceutical Biotechnology;Jan2010, Vol. 11 Issue 1, p28 

    Phage therapy--application of bacteria-specific viruses to reduce densities of pathogenic or nuisance bacteria--is a two-step process involving phage penetration to target bacteria followed by bacteria killing. Any analysis of these steps is inherently ecological as they represent...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics